Literature DB >> 24696260

PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.

Anna Pryczynicz1, Katarzyna Guzińska-Ustymowicz, Katarzyna Niewiarowska, Dariusz Cepowicz, Andrzej Kemona.   

Abstract

E-cadherin, a transmembrane adhesion molecule, and phosphatase of regenerating liver 3 (PRL-3) protein, a member of the family of tyrosine phosphatases, seem to be responsible for cancer cell migration. Therefore, the study objective was to determine a correlation between PRL-3 and E-cadherin, to assess their expression in neoplastic tissue and normal mucosa of the stomach, to analyze their effect on cancer advancement, and to evaluate their potential as prognostic markers in gastric cancer. The expressions of PRL-3 and E-cadherin were assessed immunohistochemically in 71 patients with gastric cancer. Positive expression of PRL-3 was observed in 42.2 % of gastric cancer cases, whereas E-cadherin expression was abnormal in 38 % of cases. The study revealed that the positive PRL-3 expression and abnormal E-cadherin expression were associated with mucinous gastric carcinoma and lymph node involvement. The former was also related to the infiltrating type of tumor and abnormal E-cadherin expression. The expression of PRL-3, but not of E-cadherin, was associated with shorter survival of patients. PRL-3 and E-cadherin exhibit interactions in gastric cancer and are involved in the formation of lymph node metastases. The PRL-3 protein can be an independent predictive factor of overall survival in gastric cancer patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696260      PMCID: PMC4107272          DOI: 10.1007/s13277-014-1855-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


Introduction

The phosphatase of regenerating liver 3 (PRL-3) protein belongs to the family of tyrosine phosphatases, with a unique COOH-terminal prenylation motif, and it is thus involved in a major reaction for the cell, i.e., dephosphorylation of tyrosine residues deactivating enzymes. Although its physiological role is poorly investigated, literature data suggest that PRL-3 takes part in neoformation, i.e., in migration, metastasizing, and angiogenesis [1, 2]. However, factors that regulate PRL-3 expression as well as its enzymes are not well known, and researchers are still searching for pathways and processes associated with the protein involvement. A few studies have revealed a link between PRL-3 and proteins responsible for cytoskeleton rebuilding [3-7]. Regulation of cell adhesion is another mechanism of the protein in the promotion of cancer cell invasion and metastasizing [8, 9]. The PRL-3 is also involved in tumor growth through the mechanism of epithelial-mesenchymal transformation (EMT). PRL-3 activates the Akt pathway, which results in glycogen synthase kinase 3β (GSK-3β) inactivation and then in overexpression of mesenchymal markers—vimentin, fibronectin, and Snail—and a decrease in γ-catenins, integrin β3, and E-cadherin responsible for cell adhesion [10]. E-cadherin is a transmembrane protein, which, in normal epithelium, is responsible for intracellular interactions. Its cytoplasmic domain interacts with β-catenin or γ-catenin. The complex that is formed binds α-catenin, which directly affects the cytoskeleton [11, 12]. In cancers, dysfunction of E-cadherin induced by lack of the cytoplasmic domain (no interaction with catenins) or extracellular domain (no interaction with adjacent cells with a simultaneous accumulation of catenins) and changes in mutations are observed. These disorders can lead to the detachment of cancer cells from the primary tumor mass and thus increase their invasiveness [13, 14]. Considering the similar role of both proteins in the migration of cancer cells and EMT, the objective of the current study was to determine the correlation between the PRL-3 protein and E-cadherin, to assess their expression in cancer tissue and in normal gastric mucosa, as well as to investigate their effect on tumor stage. Also, the prognostic potential of both proteins was assessed in gastric cancer.

Material and methods

The study involved 71 patients with gastric cancer treated surgically in the Second Department of General Surgery and Gastroenterology in the years 2005–2010. As a control, healthy gastric mucosa was collected from a stomach fragment removed during therapeutic surgery. The postoperative material was fixed in buffered and paraffin-embedded formalin. From paraffin blocks, 4-μm sections were cut off and stained with hematoxylin-eosin (H + E). Routine histopathological analysis included determination of tumor histological type, malignancy grade (G), anatomoclinical stage (pT), and lymph node metastases. Gastric cancers were also divided according to Lauren’s classification [15], Goseki’s classification [16], and Borrmann’s classification [17]. Also, the presence of Helicobacter pylori infection was assessed in Giemsa-stained preparations.

Immunohistochemical analysis

Tissue blocks were cut using a microtome into 4-μm-thick sections on silanized glasses. The sections were deparaffinized in xylenes and hydrated in alcohols. In order to exhibit antigen, the tissue sections were heated in a microwave for 15 min in citrate buffer (pH = 6.0). Then, they were incubated with 0.5 % hydrogen peroxide in methanol to block endogenous peroxidase and, next, with mouse anti-PRL-3 antibody (clone 3B6; Attogen Biomedical Research, USA; 1:500 dilution) overnight at 4 °C and with mouse monoclonal anti-E-cadherin antibody (clone 36B5). Following streptavidin-biotin reaction (biotinylated secondary antibody, streptavidin-HRP; Novocastra, UK), the antigen-antibody complex was visualized by application of chromogen 3,3′-diaminobenzidine (DAB; Novocastra, UK). The expressions of the proteins were assessed using the semiquantitative method, which defined PRL-3 expression as positive when the reaction was visible in more than 5 % of cancer cells and negative when there was no reaction or it was present in <5 % of cells. For E-cadherin, the reaction was normal when the membranous expression of the protein was present in >30 % of cells; it was abnormal when negative or when membranous expression was present in <30 % of cells or in the case of cytoplasmic expression. Positive reaction was calculated in at least 500 cancer cells in each tissue section using a light microscope (×400). The statistical analysis was based on Fisher’s test and χ 2 test. Log-rank test which is according to Kaplan-Meier survival analysis approach was employed to compare the overall survival rate of patients. A Cox proportional hazard model was used for univariate and multivariate analyses. A p value of <0.05 was considered statistically significant. The statistics was performed using STATISTICA 10 (Poland).

Results

PRL-3 and E-cadherin expression in normal gastric mucosa and in gastric cancer

Normal gastric mucosa did not show PRL-3 expression, whereas E-cadherin was present on the cytoplasmic membrane of most glandular cells. The neoplastic tissue had a positive expression of PRL-3 in 42.2 % (30/71) of gastric cancer cases, whereas abnormal expression of E-cadherin was observed in 38 % (27/71) of cases (Fig. 1).
Fig. 1

Immunohistochemical staining. a PRL-3 expression in the gastric mucosa. b Positive cytoplasmic PRL-3 reaction in gastric cancer cells. c Cytoplasmic membrane expression of E-cadherin in the gastric mucosa. d Negative of E-cadherin expression in gastric cancer cells. Original magnification: ×200 and ×400

Immunohistochemical staining. a PRL-3 expression in the gastric mucosa. b Positive cytoplasmic PRL-3 reaction in gastric cancer cells. c Cytoplasmic membrane expression of E-cadherin in the gastric mucosa. d Negative of E-cadherin expression in gastric cancer cells. Original magnification: ×200 and ×400

PRL-3 and E-cadherin expression in correlation to clinicopathological parameters in gastric cancer

Statistical analysis revealed no correlations of the expression of PRL-3 and E-cadherin with sex, age, tumor location, infiltration depth (pT), malignancy grade, tumor type according to Goseki and Lauren, and the presence of H. pylori infection. The positive expression of PRL-3 and abnormal expression of E-cadherin were shown to be associated with a mucinous type of gastric cancer (p = 0.002 and p = 0.012, respectively). Positive expression of PRL-3 was also related with the infiltrating type of tumor in Borrmann’s classification (p = 0.037). Patients with local lymph node involvement also had increased PRL-3 and abnormal E-cadherin expression in primary tumor (p < 0.001). Moreover, positive PRL expression was associated with abnormal expression of E-cadherin (p = 0.007) (Table 1).
Table 1

Relationship between the expressions of PRL-3 and E-cadherin proteins and clinicopathological parameters in gastric cancer

VariablesPRL-3 expression p valueE-cadherin expression p value
AbsentPresentAbnormalNormal
Age
  ≤ 5010100.41512120.358
  > 5031201532
Gender
 Male28210.88021300.591
 Female139614
Location
 Upper 1/3240.114110.568
 Middle 1/316141416
 Lower 1/323121326
Depth of invasion
 T1510.114150.794
 T211668
 T325232130
Histological differentiation
 Moderately differentiated2090.11512230.585
 Poorly differentiated21211521
Hp
 Adenocarcinoma3617 0.002 2142 0.012
 Adenocarcinoma mucinosum513105
Goseki’s classification
 I740.254350.188
 II810911
 III5565
 IV14181713
Lauren’s classification
 Intestinal type31160.05116350.086
 Diffuse type1014119
Borrmann’s classification
 I (polypoid)41 0.037 340.935
 II (fungating)84813
 III (ulcerated)26171927
 IV (infiltrative)38710
Lymph node metastasis
 Absent409 <0.001 1045 <0.001
 Present121171
Helicobacter pylori infection
 Absent16180.37315200.320
 Present20171224
E-cadherin expression
 Abnormal914 0.007
 Normal2810

Significant relationship is marked in italics

Missing data were removed in pairs

Relationship between the expressions of PRL-3 and E-cadherin proteins and clinicopathological parameters in gastric cancer Significant relationship is marked in italics Missing data were removed in pairs

Correlation of PRL-3 and E-cadherin expression with patients’ survival

Overall assessment of patients’ survival showed a lack of correlation between the expression of E-cadherin and survival rate (p = 0.510). However, the postoperative time of overall survival in patients with positive PRL-3 expression was markedly shorter (p = 0.023) (Fig. 2).
Fig. 2

Postoperative overall survival of patients with gastric cancer. Comparison of postoperative survival according to the expressions of PRL-3 and E-cadherin

Postoperative overall survival of patients with gastric cancer. Comparison of postoperative survival according to the expressions of PRL-3 and E-cadherin

Prognostic factors of gastric cancer

As shown by univariate Cox regression analysis, tumor location, histological malignancy grade, tumor type in Lauren’s classification, and positive PRL-3 expression were essential predictive factors of overall survival among gastric cancer patients (p = 0.046, 0.004, 0.021, and 0.002, respectively). Malignancy grade, tumor type in Lauren’s classification, and positive PRL-3 expression were independent predictive factors of overall survival for these patients (p = 0.006, 0.011, and 0.001, respectively) (Table 2).
Table 2

Univariate and multivariate analysis of clinicopathological factors in gastric cancer

VariablesUnivariate p valueMultivariate p valueHazard ratio95 % CI
Age (≤50 vs. >50)0.0811.6000.942–2.715
Gender (male vs. female)0.6411.1370.660–1.959
Location (upper 1/3, middle 1/3, vs. lower 1/3)0.8731.0420.627–1.730
Depth of invasion (T1, T2, vs. T3) 0.046 0.0781.8521.008–3.403
Histological differentiation (moderately diff. vs. poorly diff.)0.6411.1450.646–2.029
Hp (adc. vs. adc. mucinosum) 0.004 0.006 0.2930.127–0.678
Goseki’s classification (I and III vs. II and IV)0.8641.0730.476–2.419
Lauren’s classification (intestinal type vs. diffuse type) 0.021 0.011 2.4221.140–5.143
Borrmann’s classification (I and II vs. III and IV)0.0680.5870.331–1.040
Lymph node metastasis (absent vs. present)0.3720.7050.327–1.519
Helicobacter pylori infection (absent vs. present)0.7131.1090.635–1.937
PRL-3 expression (absent vs. present) 0.002 0.001 4.0591.615–10.198
E-cadherin expression (abnormal vs. normal)0.3180.7130.367–1.384

Significant relationship is marked in italics

Borrmann’s classification: I (polypoid), II (fungating), III (ulcerated), and IV (infiltrative)

diff. differentiated, adc. adenocarcinoma, CI confidence interval

Univariate and multivariate analysis of clinicopathological factors in gastric cancer Significant relationship is marked in italics Borrmann’s classification: I (polypoid), II (fungating), III (ulcerated), and IV (infiltrative) diff. differentiated, adc. adenocarcinoma, CI confidence interval

Discussion

EMT is a physiological process of growing embryos during which epithelial cells are transformed into mesenchymal cells. In a similar way, cancer cells of epithelial origin change into mobile mesenchymal cells. Cell junctions are lost, and cancer cells in this form are able to migrate to remote parts of the body. After being released from the primary tumor, they invade the surrounding tissues, penetrate lymphatic or blood vessels, and migrate through the vascular wall, where they eventually settle, proliferate, and induce angiogenesis. There, they become transformed into epithelial cells and adhere tightly to one another to form a metastatic tumor [18]. The ability of cancer cells to disseminate from the primary tumor to lymph nodes and to the nearest and distant tissues and organs is a major feature of malignant neoplasms and the main cause of therapeutic failure. Since tumor stage pTNM is the key factor, with the greatest significance in the treatment of gastric cancer patients, research into markers involved in metastasizing has been intensified. E-cadherin, a transmembrane adhesion molecule and PRL-3 belonging to the family of tyrosine phosphatases seem to be particularly responsible for the migration of cancer cells. Wang et al. [19] have been the first to suggest the involvement of PRL-3 in EMT. They have put forward the hypothesis that PRL-3 activates the Akt pathway through direct inhibition of PTEN (inhibitor for PI3K), which results in GSK-3β inactivation. Next, Liu et al. [20] have presented evidence for PRL-3 involvement in EMT via cadherin-related signaling pathway. Most likely, PRL-3 plays a major role in direct inhibition of the expression of E-cadherin and CDH22 [20]. In our study, we analyzed the immunohistochemical correlation between the expression of PRL-3 and E-cadherin in gastric cancer and observed a correlation between increased PRL-3 expression and abnormal E-cadherin expression (p = 0.007), which indicates that they may interact. We also compared the relationship of PRL-3 and E-cadherin with clinicopathological parameters in gastric cancer. We revealed a correlation of positive PRL-3 and abnormal E-cadherin with mucinous type of gastric cancer. Similar observations have been reported by other authors, indicating a relationship between these proteins and signet ring cell-type carcinoma [21, 22]. It is likely that an abnormal expression of E-cadherin and an overexpression of PRL-3 are associated with the loss of cell junctions and loosening of cells in this histological type. Importantly, both proteins were found to correlate with the presence of local lymph node metastases. Thus, PRL-3 and E-cadherin seem to exert an extremely significant effect on the spread of gastric cancer through the lymphatic pathway. Our findings are compatible with earlier literature data [21-24]. We also analyzed whether the proteins could be prognostic factors in gastric cancer. Only the positive expression of PRL-3 was found to correlate with shorter survival of patients. We also demonstrated that PRL-3 was an independent prognostic factor and could be used as a therapeutic target in this cancer. Ooki et al. [24] have additionally observed that PRL-3 overexpression is an independent prognostic factor in patients with gastric cancer without metastases to local lymph nodes as compared to patients with lymph node involvement. Although other studies, including the research conducted by Li et al. [25], have shown that also an abnormal expression of E-cadherin can be a strong independent prognostic factor of the overall survival of patients with gastric cancer, we did not observe such correlations for the expression of E-cadherin. In conclusion, our study found a significant correlation between PRL-3 protein and E-cadherin. However, it is the PRL-3 protein which seems to be more important in the growth of gastric cancer.
  24 in total

Review 1.  Epithelial-mesenchymal transitions in development and pathologies.

Authors:  Jean Paul Thiery
Journal:  Curr Opin Cell Biol       Date:  2003-12       Impact factor: 8.382

2.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

3.  PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.

Authors:  Haihe Wang; Samantha Yiling Quah; Jing Ming Dong; Edward Manser; Jing Ping Tang; Qi Zeng
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

4.  Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1.

Authors:  Q Zeng; W Hong; Y H Tan
Journal:  Biochem Biophys Res Commun       Date:  1998-03-17       Impact factor: 3.575

5.  Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma.

Authors:  Yin Li; Chuang-Qi Chen; Yu-Long He; Shi-Rong Cai; Dong-Jie Yang; Wei-Ling He; Jian-Bo Xu; Wen-Hua Zan
Journal:  J Surg Oncol       Date:  2012-01-09       Impact factor: 3.454

Review 6.  Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness.

Authors:  W Birchmeier; J Behrens
Journal:  Biochim Biophys Acta       Date:  1994-05-27

Review 7.  Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas.

Authors:  W Birchmeier; K M Weidner; J Hülsken; J Behrens
Journal:  Semin Cancer Biol       Date:  1993-08       Impact factor: 15.707

8.  Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma.

Authors:  N Goseki; T Takizawa; M Koike
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

9.  PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.

Authors:  James J Fiordalisi; Patricia J Keller; Adrienne D Cox
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

10.  Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3.

Authors:  Lirong Peng; Genglin Jin; Li Wang; Jianpin Guo; Lin Meng; Chengchao Shou
Journal:  Biochem Biophys Res Commun       Date:  2006-02-02       Impact factor: 3.575

View more
  10 in total

1.  E-cadherin increasing multidrug resistance protein 1 via hypoxia-inducible factor-1α contributes to multicellular resistance in colorectal cancer.

Authors:  Xi Liang; Xueqing Xu; Fengchao Wang; Ni Li; Jianming He
Journal:  Tumour Biol       Date:  2015-07-30

2.  E-Cadherin Protein as a Potential Marker for Gastric Cancer and Its Association with Helicobacter Pylori- Induced Gastritis and Gastric Ulcer.

Authors:  Mustafa Kahtan Al-Bayaty; Salma Abdul-Rudha Abass; Mohammed Faraj Al-Marjani
Journal:  Rep Biochem Mol Biol       Date:  2019-10

3.  Prognostic significance of E-cadherin expression in hepatocellular carcinoma: a meta-analysis.

Authors:  Jiang Chen; Jie Zhao; Rui Ma; Hui Lin; Xiao Liang; Xiujun Cai
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

Review 4.  Regulatory mechanisms of phosphatase of regenerating liver (PRL)-3.

Authors:  Teresa Rubio; Maja Köhn
Journal:  Biochem Soc Trans       Date:  2016-10-15       Impact factor: 5.407

5.  PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.

Authors:  Qian Dong; Xueqiang Ding; Boyang Chang; Haihe Wang; Anxun Wang
Journal:  J Oral Pathol Med       Date:  2015-06-03       Impact factor: 4.253

6.  Prediction of onset of remnant gastric cancer by promoter DNA methylation of CDO1/HOPX/Reprimo/E-cadherin.

Authors:  Keita Kojima; Naoko Minatani; Hideki Ushiku; Satoru Ishii; Toshimichi Tanaka; Keigo Yokoi; Nobuyuki Nishizawa; Yosuke Ooizumi; Kazuharu Igarashi; Kei Hosoda; Hiromitsu Moriya; Hiroaki Mieno; Masahiko Watanabe; Keishi Yamashita
Journal:  Oncotarget       Date:  2019-03-29

7.  Overexpressed lncRNA GATA6-AS1 Inhibits LNM and EMT via FZD4 through the Wnt/β-Catenin Signaling Pathway in GC.

Authors:  Zheng-Tian Li; Xu Zhang; Da-Wei Wang; Jun Xu; Ke-Jian Kou; Zhi-Wei Wang; Gong Yong; De-Sen Liang; Xue-Ying Sun
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-22       Impact factor: 8.886

8.  A retrospective cohort study of clinical value of PRL-3 in stage III human colorectal cancer.

Authors:  Chuanyuan Liu; Wu Zhong; Laiyang Xia; Chuanfa Fang; Hongquan Liu; Xiaochun Liu
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

Review 9.  Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.

Authors:  Zhifang Jia; Min Zheng; Jing Jiang; Donghui Cao; Yanhua Wu; Yuzheng Zhang; Yingli Fu; Xueyuan Cao
Journal:  BMC Cancer       Date:  2022-02-08       Impact factor: 4.430

10.  Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.

Authors:  Esten N Vandsemb; Helena Bertilsson; Pegah Abdollahi; Øystein Størkersen; Thea Kristin Våtsveen; Morten Beck Rye; Torstein Baade Rø; Magne Børset; Tobias S Slørdahl
Journal:  J Transl Med       Date:  2016-03-15       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.